These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38722496)

  • 1. Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.
    Swift C; Frazer MS; Gronroos NN; Sargent A; Leszko M; Buysman E; Alvarez S; Dunn TJ; Noone J; Guevarra M
    Diabetes Ther; 2024 Jul; 15(7):1547-1559. PubMed ID: 38722496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.
    Frazer M; Swift C; Gronroos NN; Sargent A; Leszko M; Buysman E; Alvarez S; Dunn TJ; Noone J; Guevarra M
    Adv Ther; 2023 Nov; 40(11):5102-5114. PubMed ID: 37740832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.
    Swift C; Frazer M; Gronroos NN; Sargent A; Leszko M; Buysman E; Alvarez S; Dunn TJ; Noone J; Guevarra M
    Diabetes Obes Metab; 2024 Jun; 26(6):2111-2118. PubMed ID: 38418411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Semaglutide Reduces HbA
    Pratley RE; Crowley MJ; Gislum M; Hertz CL; Jensen TB; Khunti K; Mosenzon O; Buse JB
    Diabetes Ther; 2021 Apr; 12(4):1099-1116. PubMed ID: 33660198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
    Ramos M; Cummings MH; Ustyugova A; Raza SI; de Silva SU; Lamotte M
    Diabetes Ther; 2020 Sep; 11(9):2041-2055. PubMed ID: 32700188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
    Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
    Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 16. Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy.
    Hazel-Fernandez L; Xu Y; Moretz C; Meah Y; Baltz J; Lian J; Kimball E; Bouchard J
    Curr Med Res Opin; 2015; 31(9):1703-16. PubMed ID: 26154837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes.
    Candido R; Gaiotti S; Giudici F; Toffoli B; De Luca F; Velardi V; Petrucco A; Gottardi C; Manca E; Buda I; Fabris B; Bernardi S
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
    Mody R; Yu M; Nepal B; Konig M; Grabner M
    Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study.
    Kick A; M'Rabet-Bensalah K; Acquistapace F; Amadid H; Ambühl RA; Braae UC; Item F; Schultes B; Züger T; Rudofsky G
    Diabetes Ther; 2024 Mar; 15(3):623-637. PubMed ID: 38240875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?
    RoyChaudhuri S; Majumder A; Sanyal D; Chakraborty S; Chuyan S
    Cureus; 2023 Apr; 15(4):e37065. PubMed ID: 37153287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.